Stephen Willey: Yes, good afternoon. Thanks for taking the questions. I guess now that you’ve remove the control arm from TAMARACK? I’m guessing there’s going to be more of an emphasis on response rate versus, I guess, any kind of event-driven efficacy data. So, I guess I’m just curious based upon the eligibility criteria of TAMARACK? What percentage of patients you’re expecting to actually have soft tissue disease that is resist valuable?
Scott Koenig: With that from that parameter, I think our experience in many of — in the trials to date have at least half those patients, and I would not be surprised given this is an international study based on actually the results from the Lori trial that we presented almost all of the majority of those patients had visceral involvement that was not only involvement. So, I’m not at this point, I am not concerned that we will be seeing a tissue limited population. I think there will be enough data to that. And then clearly, we’ll monitor that going forward, and we certainly can add more patients if necessary, but I don’t think that’s going to be a problem.
Stephen Willey: Okay. And I guess just a question on vobra duo. So, you’ve pressed the pause button here on single-agent dose expansion in other tumor types. I think that’s despite some of the early signs of efficacy that you talked about earlier. Are you thinking of reinitiating any of those development efforts again once you get confirmation on dosing and scheduling from TAMARACK or does this next-gen ADC effort now kind of get prioritized in front of vobra duo?
Scott Koenig: Yes, I mean my answer to you is we certainly are interested given the broad expression of B7-H3 across a large number of solid tumors and our experience with them that additional tumor types will be pursued. Clearly, we would like to see with vobra duo, that improvement in safety, which I discussed earlier. And one — and I mean I can guess at this point, or we could forge ahead and just move that, but I think it’s more prudent given, as I said earlier today, that enrollment is going well, and we’ll have the answer soon to initiate other types at that point. We feel very strongly that we are building a great opportunity and franchise within prostate cancer with the Lori, with vobra potential combination. And then as we said today, the plans to start with academic collaborators, a neoadjuvant study with enoblituzumab in prostate cancer.
So, we’re trying to really cover the entire landscape for treatment of patients with prostate, but that does not interfere with our enthusiasm for pursuing this in other tumors as well.
Stephen Willey: All right. thanks for taking the questions.
Operator: Thank you. Our next question comes from Jon Miller with Evercore ISI. Your line is open.
Jon Miller: Hi guys. Thanks for taking the questions. I would look to ask more about the financials and the runway guidance. So, obviously, you mentioned that covers TAMARACK and Lori Phase 2 an ongoing trial. How much does that cover of a new ADC? How much does that cover four trials that aren’t currently running our anticipated start? And does that count any new indications, either for vobra duo or for Lori in expansion?
Scott Koenig: Yes. Thanks Jon. Very good question. Obviously, with today’s announcement, we’re very excited about getting that additional $50 million milestone from achieving it through the results of the PROTECT study. And so obviously, just again to put in context, as we said earlier, with the 320 million in the past, you have non-diluted capital, the likelihood of additional milestones goes up because of the — hitting the primary endpoint. Of course, it’s dependent on the opportunity to get TZIELD approved in the new indication as well as different regions for the original indication that has been already approved in the US FDA, but that increase is likelihood there, which means potential increased opportunities for more milestones and as well as royalties.
